Lisata Therapeutics cuts workforce about 72% in reorganization
LSTA•Corporate reorganization cuts workforce
Lisata Therapeutics began a corporate reorganization on Aug. 3, 2026, cutting its workforce by about 72% effective immediately.
The move targets lower operating expenses as the company pursues strategic options.
Restructuring costs and executive changes
Restructuring costs are expected to be about $1.2 million, mainly severance and termination benefits, incurred through the quarter ending Sept. 30, 2026.
Executive Vice President of R&D and Chief Medical Officer Kristen K. Buck was terminated; her contract provides 12 months of base salary and target bonus, plus COBRA coverage for up to 12 months.
The board authorized a $200,000 cash retention bonus for Chief Accounting Officer James Nisco, payable within 30 days of Dec. 31, 2026, subject to continued employment.
